Objective. miRNAs, which are non-coding RNAs, play a role in the pathogenesis of disease including OA. miRNA (miR)-34a is induced by p53, subsequently leading to cell apoptosis, which is one of the major factors in the pathogenesis of OA. The purpose of this study is to investigate the effect of silencing miR-34a on IL-1b-induced chondrocyte apoptosis in a rat OA model in vitro.
Introduction
Normal cartilage homeostasis and structural integrity depend on chondrocytes, which account for only 5% of the total cartilage volume. Chondrocytes maintain the dynamic equilibrium between production of the extracellular matrix and its enzymatic degradation. Loss of this balance in favour of catabolic events results in the loss of articular cartilage seen in OA. Thus, chondrocyte viability is essential for maintaining the integrity of articular cartilage; moreover, reduced cellularity may predispose to matrix degeneration and may be associated with the onset or progression of OA [1, 2] .
Apoptosis is a highly regulated form of cell suicide and during normal development constitutes a physiological mechanism by which unwanted cells are eliminated. Nevertheless, apoptosis is often involved in pathogenetic pathways. Chondrocyte apoptosis has recently been linked to OA pathogenesis by many investigators [3] [4] [5] [6] [7] . Decreased tissue cellularity due to cell death, linked to an increase in the number of empty lacunae in the cartilage, has been demonstrated in OA patients. Studies performed in situ have evidenced a higher number of apoptotic chondrocytes in OA compared with normal samples. Therefore, the effective prevention of chondrocyte apoptosis might become one of the therapeutic strategies for OA treatment.
miRNAs are a family of $22-nt endogenous non-coding RNAs identified in organisms ranging from nematodes to humans. Many miRNAs are evolutionarily conserved across phyla, regulating gene expression by post-transcriptional gene repression by binding the target mRNA's 3 0 -UTR [8] [9] [10] . Several miRNAs exhibit a tissue-specific or developmental stage-specific expression pattern and have been reported to be associated with conditions such as cancer and viral infection [11] [12] [13] . In OA cartilage, several studies demonstrated that miRNA might play a role in OA pathogenesis [14] [15] [16] [17] [18] .
miRNA (miR)-34a has been reported to have an anti-proliferative potential and to play a role in the regulation of cell cycle transition from G1 to S. miR-34a is also induced by p53, subsequently leading to cell apoptosis, or cell cycle arrest [18] [19] [20] . Its abnormal expression has been correlated with several human diseases including cancer and leukaemia [18, 21, 22] . It was reported that silencing of miR-34a by miR-34a-specific locked nucleotide analogues (LNAs) could reduce the cell apoptosis induced by DNA damage [19] .
We hypothesize that silencing of miR-34a by miR-34a-specific LNA anti-sense could prevent cartilage degradation via inhibition of chondrocyte apoptosis. The purpose of this study is to investigate the effect of silencing miR-34a by miR-34a-specific LNA anti-sense on IL-1b-induced chondrocyte apoptosis in a rat OA model in vitro.
Materials and methods

Animals
Sprague-Dawley rats weighing 200-250 g were used.
Rats were housed at the Laboratory Animal Center in Hiroshima University under standard diurnal conditions and were fed a standard commercial diet and given tap water ad libitum. This study was reviewed and approved by the Ethics Committee for Experimental Animals of Hiroshima University, and all animals were treated according to the guidelines of the Institutional Animal Care and Use Committee.
Cell culture Articular chondrocytes were isolated from the knee joints of rats as previously described [23] . Articular cartilage tissues were cut into small pieces (<1 mm 3 ) and digested with 0.2% trypsin and 0.2% Type II collagenase for 30 min and 2 h, respectively. The released cells were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. Primary cells were maintained in monolayer culture in this study. After the cells reached confluence, transfection of LNA-modified DNA oligonucleotides in various concentrations was performed using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's protocols. The sequences of LNA-modified DNA oligonucleotides are as follows: LNA-miR-34a (miR-34a inhibitor); 5 0 -ACA ACC AGC TAA GAC ACT-GCC A-3 0 , and that of LNA-miR-34a mutation (miR-34a inhibitor mt); 5 0 -AGT TCC AGC TAA GAC ACT CGG A-3 0 . miR-34a inhibitor mt has 6-nt substitutions disrupting the base pairing with miR-34a. After 12 h, IL-1b (R&D systems Inc., Minneapolis, MN, USA) was added to the culture medium. Each experiment was repeated at least three times.
Synthesis of complementary DNA
Total RNA yields were calculated and quality was determined using absorption spectrochemical analysis. One microgram of total RNA was reverse-transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, Chatsworth, CA, USA) according to the manufacturer's protocol. The genomic DNA elimination reaction was carried out using 2 ml of gDNA wipeout buffer, 1 mg (1 ml) template RNA and 11 ml RNase-free water at 42 C for 2 min. Reverse transcription was performed in 1 ml quantiscript reverse transcriptase, 4 ml quantiscript RT buffer, 1 ml RT primer mix and 14 ml template RNA (the entire genomic DNA elimination reaction) at 42 C for 15 min and 95 C for 3 min and then the complementary DNA (cDNA) product was maintained at 4 C.
Quantitative (real-time) PCR
Quantitative RT-PCR assays were performed using a TaqMan miRNA assay kit (Applied Biosystems, CA, USA) for mature miRNAs and SYBR Green (Invitrogen, Carlsbad, CA, USA) for the rat Col2a1 and iNOS.
Reverse transcriptase reactions of mature miRNAs contained a sample of total RNA, 50 nM stem-loop RT primer, 10Â RT buffer, 100 mM each dNTPs, 50 U/ml MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA, USA) and 20 U/ml RNase inhibitor. Fifteen-microlitre reactions were incubated in a thermocycler (BioRad, Hercules, CA, USA) for 30 min at 16 C, 30 min at 42 C, 5 min at 85 C and held at 4 C. Real-time PCR was performed using a Mini Opticon Real-time PCR System (BioRad) in a 10 ml PCR mixture containing 1.33 ml RT product, 2Â TaqMan Universal PCR Master Mix, 0.2 mM TaqMan probe, 15 mM forward primer and 0.7 mM reverse primer. Each SYBR Green reaction was performed with 1.0 ml template cDNA, 10 ml SYBR Green mix, 1.5 mM primer and water to adjust the final volume to 20 ml. Primer sequences were as follows: rat Col2a1, 5 0 -TCC TAA GGG TGC CAA TGG TGA-3 0 (forward), 5 0 -AGG ACC AAC TTT GCC TTG AGG AC-3 0 (reverse); rat iNOS, 5 0 -ACC CAA GGT CTA CGT TCA AG-3
(reverse); and rat ACTB, 5 0 -GAT CAT TGC TCC TCC-TGA GCG-3 0 (forward), 5 0 -TGC TGA TCC ACA TCT GCT-GGA-3 0 (reverse). All reactions were incubated in a 48-well plate at 95 C for 10 min, followed by 40 cycles of 95 C for 15 s and 60 C for 1 min and performed in triplicate. The snoRNA135 or ACTB gene was used as a control to normalize differences in total RNA levels in each transcript. A threshold cycle (C T ) was observed in the exponential phase of amplification, and quantification of relative expression levels was performed using standard curves for target genes and the endogenous control. Geometric means were used to calculate the ÁÁC T values and expressed as 2
ÀÁÁCT
. The value of each control sample was set at 1 and used to calculate the fold change of target genes.
www.rheumatology.oxfordjournals.org Immunocytochemistry Twenty-four hours after the addition of IL-1b, immunohistochemistry was performed. The cells were fixed in cold methanol for 2 min, and washed in PBS for 10 min at room temperature (RT). Afterwards, the cells were washed three times in PBS, and incubated in blocking buffer for 30 min at RT. After washing the cells in PBS, they were incubated overnight at 4 C with rabbit primary antibody of Type II collagen (Chemicon, Temecula, CA, USA). After washing the cells in PBS, they were incubated with secondary antibody using Alexa Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes; Invitrogen) for 1 h at RT. 4,6,-diamidino-2-phenylindole (DAPI; Dojindo Laboratory, Kumamoto, Japan) solution was applied for 5 min for nuclear staining.
Toluidine blue staining
The cells were fixed in cold methanol for 2 min, and washed in PBS for 10 min at RT. Afterwards, the cells were washed three times in PBS. Then the cells were stained with 0.5% toluidine blue, and observed under light microscopy.
Assessment of cell viability
Chondrocytes were grown in the appropriate medium supplemented with 10% FBS in 96-well culture plates at a density of 5 Â 10 3 cells/well and allowed to adhere overnight. Next day, miR-34a-specific LNA or miR-34a-specific LNA mutation was transfected into cells according to the manufacturer's protocol. The chondrocyte culture was then treated with IL-b. The viable cell amount was measured at 24 and 48 h by Cell Counting Kit-8 (Dojindo Laboratory, Kumamoto, Japan), according to the manufacturer's instructions. In brief, a 10% working solution including 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium monosodium salt (WST-8) was added to each well, and cultures were incubated for 4 h at 37 C. The absorbance was measured at 450 nm (reference wavelength 690 nm) using a microplate reader (SPECTRAmax190; Molecular Devices, Sunnyvale, CA, USA). Cell viability was expressed as a fold change in the control (IL-1b only). This is a measure of metabolic activity with the assumption that this is not altered by IL-1b treatment, and therefore it acts as a measure of viability.
TUNEL staining
Twenty-four hours after transfection, TUNEL staining was performed according to the manufacturer's protocol (DeadEnd Fluorometric TUNEL System; Promega, WI, USA). The cells were fixed in 4% formaldehyde in PBS for 25 min at 4 C, and washed three times in PBS. Afterwards, equilibration buffer was added, and equilibration at RT for 10 min was performed. TdT reaction mix was added to the cells and incubated at 37 C for 60 min. After that, the cells were incubated in 2Â SSC for 15 min. To visualize all nuclei, DAPI solution was applied for 5 min.
Statistical analysis
Statistical analysis was performed by Tukey-Kramer or one-way analysis of variance and subsequent Fisher's least significant difference test. P < 0.05 was considered to be statistically significant.
Results
The expression of miR-34a induced by IL-1b-mediated cell apoptosis
To investigate whether the expression of miR-34a was induced by IL-1b, rat primary chondrocytes were incubated with various concentrations of IL-1b (0, 1, 10 ng/ml) for 24 h. The expression level of miR-34a was up-regulated 1.57 (0.08)-fold at the 1 ng/ml concentration of IL-1b, and 2.87 (1.38)-fold at the 10 ng/ml concentration of IL-1b. The expression of miR-34a was significantly induced by IL-1b in a dose-dependent manner (Fig. 1) .
MiR-34a-specific LNA could prevent chondrocyte apoptosis induced by IL-1b
To examine the effect of silencing miR-34a on chondrocyte apoptosis, miR-34a inhibitor was transfected into rat chondrocytes. After the transfection, rat chondrocytes were treated by IL-1b for 24 h. Real-time PCR revealed that miR-34a inhibitor significantly inhibited the up-regulation of miR-34a expression by IL-1b in a dose-dependent manner (Fig. 2) . Real-time PCR also revealed that IL-1b significantly reduced the expression of Col2a1 as well as significantly induced up-regulation of iNOS. Also, MiR-34a inhibitor significantly prevented the IL-1b-induced down-regulation of Col2a1, as well as IL-1b-induced up-regulation of iNOS (Fig. 3A) . Immunohistochemical analysis and toluidine blue staining revealed that miR-34a inhibitor can effectively inhibit the IL-1b-induced down-regulation of Type II collagen protein level (Fig. 3B) . Viable cell amount was significantly decreased by the treatment of IL-1b, and this decrease was more pronounced after 48 h, which is highly statistically significant. However, miR-34a inhibitor significantly inhibited the decrease in cell viability at 48 h (Fig. 4) . Moreover, miR-34a inhibitor could reduce the TUNEL-positive cells compared with miR-34a inhibitor mutation and IL-1b only (Fig. 5) . Consequently, inhibition of up-regulated miR-34a was effective in the prevention of IL-1b-induced chondrocyte apoptosis.
Discussion
Quite recently, miRNA attracted attention because it plays a crucial role in human disease and can be a potentially new therapeutic target. For example, the expression of let-7 may play a critical role in lung cancer by causing high expression of the RAS gene [24] . Also, the expression of miR-143 and miR-145 is reduced in colon cancer, and other studies reported evidence for roles of miRNAs in human diseases such as leukaemia, viral infection and DiGeorge syndrome [25] [26] [27] [28] . Several therapeutic trials in vivo have been conducted [29, 30] . Members of the miR-34 family are induced by p53, leading to apoptosis, cell cycle arrest and senescence through targeting E2F3, cyclin E2, CDK6, etc. [18] [19] [20] . Recent studies demonstrated that miR-34a is the most significantly induced miRNA after activation of p53 leading to global alterations in gene expression, cell cycle arrest and apoptosis as common endpoints of p53 activation. In human cancers, miR-34a is a direct transcriptional target of p53 and is an important component of the p53 tumour suppressor network that is commonly deleted [20] [21] [22] . It was found that miR-34a acts as a potential tumour suppressor by inducing apoptosis in neuroblastoma cells possibly through direct targeting of the mRNA encoding E2F3 and significantly reducing the levels of E2F3 protein, a potent transcriptional inducer of cell cycle progression. Tazawa et al. [22] demonstrated that miR-34a is down-regulated in human colon cancer, and that tumour growth in mice is significantly inhibited by the administration of double-stranded miR-34a/ atelocollagen complex. They proved that miR-34a is a crucial factor in the pathogenesis of colon cancer, and that therapeutic potential for cancer exists by targeting miR-34a [22] .
In OA cartilage, it has been clarified that miRNAs play a role in OA progression [14] [15] [16] [17] . Yamasaki et al. [16] reported that miR-146 is intensely expressed in low-grade OA cartilage, and that its expression is induced by the stimulation of IL-1b. Miyaki et al. [17] demonstrated that the reduction in miR-140 expression in OA cartilage might contribute to the abnormal gene expression pattern characteristic of OA. Chondrocyte apoptosis is one of the major factor in the progression of OA. Therefore, we investigated the expression of miR-34a in OA cartilage, and confirmed that the expression of miR-34a tended to increase as the cartilage degradation increases (data not shown). According to these results, we also examined the therapeutic potential of silencing miR-34a by miR-34-specific LNA in vitro.
In the current study, miR-34-specific LNA inhibited down-regulation of Col2a1, and up-regulation of iNOS, one of the main causes of articular chondrocyte apoptosis [31] [32] . However, the function of miR-34a in chondrocyte apoptosis through the inhibition of its target genes is still unclear. One miRNA has hundreds of target genes by computational analysis [33] . Therefore, many molecular networks exist that could be involved in chondrocyte apoptosis.
Emerging evidence has proved that LNA-modified DNA oligonucleotides can be a potentially useful tool for therapeutic intervention in vivo. It was proved that systemic administration of LNA-anti miRNAs could function without any toxicity in non-human primates [34] . This present   FIG. 4 Assessment of cell viability by 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl) -2H-tetrazolium monosodium salt (WST-8). The cell viability was expressed as a fold change of the control (IL-1b only). IL-1b markedly decreased the viable cell count especially at 48 h. **P < 0.01. miR-34a inhibitor significantly inhibited the decrease of cell viability at 48 h. *P < 0.05. mt: mutation. study revealed that silencing of miR-34a by miR34a-specific LNA might develop a novel intervention for OA treatment through the prevention of cartilage degradation.
In conclusion, our study demonstrated that the expression of miR-34a is induced by IL-1b in chondrocytes, and that LNA-modified miR-34a anti-sense can prevent the down-regulation of Col2a1 and up-regulation of iNOS mediated by IL-1b in chondrocytes. Finally, silencing miRNA-34a can prevent chondrocyte apoptosis.
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